ArticleBJU international2026
Prostate-specific antigen testing and prostate cancer-related outcomes: a Danish nationwide study.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo assess the prostate-specific antigen (PSA) testing and prostate cancer-related outcomes in a national, publicly funded healthcare setting, with recommendations against testing of asymptomatic men. SUBJECTS AND
methodsAll men born between 1920 and 1970, alive and residing in Denmark on 1 January 2014, were quarried in the national health registries. Age-standardised rates (ASR) per 100 000 men for men aged >50 years and cumulative incidence at 100 years by Aalen Johansen estimator with delayed entry were estimated for PSA testing, prostate histology, biopsy, prostate cancer diagnosis, and prostate cancer-specific death.
resultsAmong 1 371 099 eligible men, the ASR of PSA testing in 2023 was 14 659 tests per 100 000 men (95% confidence interval [CI] 14 585-14 733), and 21 828 tests per 100 000 men (95% CI 21 646-22 111) in men aged 70-79 years. Cumulative incidence at 100 years of a PSA test was 84% (95% CI 84-84%), prostate histology 20% (95% CI 20-20%), biopsy 15% (95% CI 15-15%), prostate cancer diagnosis 12% (95% CI 11-12%), and prostate cancer-specific death 5.0% (95% CI 5.0-5.1%). The median (interquartile range [IQR]) age at initial PSA test was 60 (52-67) years, 70 (64-76) years at prostate histology and biopsy, 72 (66-78) years at prostate cancer diagnosis, and 84 (78-89) years at prostate cancer-specific death.
conclusionsIn Denmark PSA testing rates are high and prevalent in older ages, despite restrictive national guidelines and active training against PSA testing for general practitioners. The findings support the discussion of whether the availability of the PSA test should be reconsidered to minimise the harms associated with unnecessary testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.